Mahamaya Lifesciences Ltd
ncorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration and export of finest crop protection products and bioproducts for crop & soil health management.[1]
- Market Cap ₹ 266 Cr.
- Current Price ₹ 114
- High / Low ₹ 122 / 111
- Stock P/E 20.6
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 25.9 %
- ROE 34.9 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 28.5%
Cons
- Debtor days have increased from 52.1 to 67.0 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Fertilizers & Agrochemicals Pesticides & Agrochemicals
Part of BSE SME IPO
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 90 | 137 | 161 | 264 | |
| 84 | 128 | 148 | 241 | |
| Operating Profit | 6 | 9 | 13 | 23 |
| OPM % | 7% | 6% | 8% | 9% |
| 0 | 0 | 1 | 3 | |
| Interest | 2 | 3 | 6 | 7 |
| Depreciation | 1 | 1 | 1 | 2 |
| Profit before tax | 4 | 5 | 7 | 17 |
| Tax % | 27% | 26% | 27% | 25% |
| 3 | 4 | 5 | 13 | |
| EPS in Rs | 21.78 | 30.03 | 41.80 | 7.28 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 43% |
| TTM: | 63% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 68% |
| TTM: | 149% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 29% |
| Last Year: | 35% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 18 |
| Reserves | 14 | 18 | 23 | 32 |
| 19 | 24 | 55 | 58 | |
| 21 | 34 | 33 | 81 | |
| Total Liabilities | 56 | 78 | 112 | 188 |
| 20 | 21 | 21 | 27 | |
| CWIP | 2 | 2 | 3 | 4 |
| Investments | 0 | 0 | 0 | 0 |
| 34 | 54 | 88 | 157 | |
| Total Assets | 56 | 78 | 112 | 188 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 2 | 1 | -23 | 1 | |
| -3 | -3 | -2 | -8 | |
| 1 | 2 | 24 | 9 | |
| Net Cash Flow | 0 | 1 | -0 | 1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 37 | 25 | 64 | 67 |
| Inventory Days | 93 | 109 | 137 | 167 |
| Days Payable | 83 | 87 | 61 | 92 |
| Cash Conversion Cycle | 47 | 48 | 140 | 142 |
| Working Capital Days | 8 | 9 | 14 | 29 |
| ROCE % | 20% | 21% | 26% |
Documents
Annual reports
No data available.
Business Profile[1]
The company manufactures pesticide formulations and supplies bulk products to Indian agrochemical companies and multinational corporations (MNCs). It imports scientifically researched molecules, secures registrations with the Central Insecticides Board, and develops these molecules into technical-grade and value-added formulations, which are marketed to domestic manufacturers and global MNCs.